Saol Therapeutics Inc
Quick facts
Phase 3 pipeline
- SL1002 · Oncology, Virology, Immunology
SL1002 is a recombinant human serum albumin-interferon alpha fusion protein that enhances innate immune responses against viral infections and cancer.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: